AADAPT - Analysis of Advagraf Dose Adaptation Post Transplantation

Mise à jour : Il y a 4 ans
Référence : NCT01435291

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

A pharmacokinetics and pharmacogenetics study to complement the current knowledge of tacrolimus prolonged release (Advagraf®) in the immediate post-transplantation period and at steady-state (M3 post transplantation) and to improve the optimal dose of Advagraf® based on tacrolimus AUC estimated by two Limited Samples Strategies during the first 3 months after renal transplantation. Data obtained with tacrolimus prolonged release will be compared with those of tacrolimus immediate release (Prograf®)


Critère d'inclusion

  • renal transplantation

Liens